Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

SAB Biotherapeutics (SABS) EBITDA (2021 - 2025)

SAB Biotherapeutics (SABS) has disclosed EBITDA for 5 consecutive years, with -$9.7 million as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, EBITDA rose 4.6% year-over-year to -$9.7 million, compared with a TTM value of -$41.3 million through Jun 2025, down 148.97%, and an annual FY2025 reading of $13.6 million, up 139.68% over the prior year.
  • EBITDA was -$9.7 million for Q2 2025 at SAB Biotherapeutics, up from -$10.0 million in the prior quarter.
  • Across five years, EBITDA topped out at $10.3 million in Q4 2023 and bottomed at -$12.7 million in Q4 2021.
  • Average EBITDA over 5 years is -$6.4 million, with a median of -$7.4 million recorded in 2023.
  • The sharpest move saw EBITDA tumbled 924.07% in 2022, then surged 231.63% in 2023.
  • Year by year, EBITDA stood at -$12.7 million in 2021, then soared by 38.06% to -$7.9 million in 2022, then soared by 231.63% to $10.3 million in 2023, then plummeted by 196.74% to -$10.0 million in 2024, then grew by 2.77% to -$9.7 million in 2025.
  • Business Quant data shows EBITDA for SABS at -$9.7 million in Q2 2025, -$10.0 million in Q4 2024, and -$11.3 million in Q3 2024.